Real life results of direct acting antiviral therapy for HCV infection in HIV-HCV-coinfected patients: Epi-Ter2 study.

The aim of this study was to evaluate the baseline demographics and real-life efficacy of direct acting antivirals (DAAs) in HIV-HCV-positive patients as compared to patients with HCV monoinfection. The analysis included 5690 subjects who were treated with DAAs: 5533 were HCV-positive and 157 were HIV-HCV-positive. Patients with HCV-monoinfection were older ( < .0001) and in HIV-HCV group there were more men ( < .0001). Prevalence of genotype 1a ( = .002), as well as of genotypes 3 and 4 ( < .0001) was higher in HIV-HCV-coinfected patients. Genotype 1b was more frequent ( < .0001) in the HCV-mono-infection group. Patients with HCV-monoinfection had a higher proportion of fibrosis F4 ( = .0004) and lower proportion of fibrosis F2 ( < .0001). HIV-HCV-coinfected individuals were more often treatment-naïve ( < .0001). Rates of sustained viral response after 12 weeks did not differ significantly between both groups (95.9% versus 97.3% in coinfection and monoinfection group, respectively; > .05). They were, however, influenced by HCV genotype ( < .0001), stage of hepatic fibrosis ( < .0001), male sex ( < .0001), BMI ( = .0001) and treatment regimen modifications ( < .0001). Although factors associated with worse response to therapy (male sex, genotype 3) occurred more often in the HIV coinfection group, real-life results of DAAs did not differ significantly between both populations.